Skip to content

Author

M. Schou

We have 7 of 52 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Nov 2026

Abstract 6518: Kidney Failure Risk Equation, Clinical Outcomes, and Effect of Finerenone in HFmrEF/HFpEF: Insights from FINEARTS-HF

Background: The Kidney Failure Risk Equation (KFRE) is recommended in international guidelines for estimating the risk of kidney failure in patients with chronic kidney disease (CKD). The prognostic relevance of the KFRE has not been described in patients with heart failure and mildly reduced or preserved ejection f...

R. Ono, K. Docherty, A. Henderson et al. · 0 citations
Open access Oct 2026

The antifibrotic effect of empagliflozin: Insights from the EMPIRE trial programme

Treatment with empagliflozin significantly decreased levels of circulating PRO-C3, reflecting attenuated systemic fibroblast activation, and to what extent this indicated antifibrotic effect may underpin the clinical effects of empagliflozin remains to be elucidated.

J. Jensen, C. Andersen, M. Omar et al. · 0 citations
Aug 2026

Venous thromboembolism in 5-year cancer survivors: a nationwide cohort study.

Survivors of all 21 cancer subtypes had a higher associated rate of VTE compared with the background population, with the highest incidence rates found for multiple myeloma.

A. Yafasova, Guo-Li Sun, M. Hutchings et al. · 0 citations
Oct 2026

Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.

BACKGROUND For persons living with both type 2 diabetes and obesity, weight management may be the most effective therapy for type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor agonists have potent weight-reducing effects, and other mechanisms may confer additional benefits. Survodutide is an investigational gluc...

Sean Wharton, C. L. le Roux, E. Startseva et al. · 0 citations
Open access Aug 2026

HFpEF-ABA Score and Finerenone in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: Insights From the FINEARTS-HF Trial.

BACKGROUND The HFpEF-ABA score is a simple diagnostic tool developed to estimate the probability of heart failure with preserved ejection fraction (HFpEF) using age, body mass index, and history of atrial fibrillation. OBJECTIVES This study aims to evaluate the HFpEF-ABA score in patients with confirmed heart failure...

R. Ono, K. Docherty, A. Henderson et al. · 0 citations
Open access Aug 2026

Personalized evaluation of NT-proBNP and clinical characteristics in suspected heart failure: the PRECISE-HF study.

BACKGROUND AND AIMS N-terminal pro-B-type natriuretic peptide (NT-proBNP) is recommended to guide echocardiography referral in community-based patients with suspected heart failure (HF), but diagnostic performance is influenced by individual characteristics including age, ethnicity, kidney function, cardiac rhythm, and...

K. Docherty, B. Heywood, L. Anderson et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.